SCHEMBL6691352

SCHEMBL6691352

NC(=O)c1nc(-c2ccc(Cl)cc2)[nH]c1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.52
IKBKB O14920 1/20 0.51
CHEK2 O96017 15/20 0.51
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
THRB P10828 1/20 0.46
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
APP P05067 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
NFKB1 P19838 1/20 0.44
SNCA P37840 1/20 0.44
RAB9A P51151 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11485417 0.84 PARP1 (0.52) PARP1IKBKBCHEK2MEN1KMT2A
SCHEMBL6691823 0.83 PIN1 (0.56) PARP1IKBKBCHEK2MEN1KMT2A
SCHEMBL3993126 0.79 DGAT1 (0.51) PARP1CHEK2GAAMAPTHSD17B10
SCHEMBL6691354 0.79 PARP1 (0.56) PARP1CHEK2NPC1ALDH1A1GAA
SCHEMBL10694623 0.79 PARP1 (0.51) PARP1IKBKBCHEK2MEN1KMT2A
SCHEMBL3997493 0.78 KDM4E (0.54) PARP1CHEK2KDM4ENPC1ALDH1A1
SCHEMBL5126528 0.76 MEN1 (0.55) CHEK2MEN1KMT2A
SCHEMBL8964072 0.71 PIN1 (0.55) PARP1CHEK2MEN1KMT2AKDM4E
SCHEMBL11481631 0.70 PARP1 (0.52) PARP1CHEK2ALDH1A1GAAHPGD
SCHEMBL11470960 0.69 CHEK2 (0.48) PARP1IKBKBCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040006118-A1 Nf-kb inhibitors SMITHKLINE BEECHAM CORPORATION 2004-01-08 US claimed
EP-1328272-A1 NF-KAPPA-B INHIBITORS SmithKline Beecham Corporation (US) 2003-07-23 EP claimed
WO-2002030423-A1 NF-λB INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-18 WO claimed
US-20040006118-A1 Nf-kb inhibitors SMITHKLINE BEECHAM CORPORATION 2004-01-08 US disclosed
EP-1328272-A1 NF-KAPPA-B INHIBITORS SmithKline Beecham Corporation (US) 2003-07-23 EP disclosed
WO-2002030423-A1 NF-λB INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006118-A1 Nf-kb inhibitors NFKBIA, IKBKB, IKBKG PARP1 1567/4885IKBKB 2/4885CHEK2 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.